ArticleBMC infectious diseases2026
Distinct molecular epidemiology and outcomes of carbapenem-resistant gram-negative infections in Lebanon: insights from the MDRO network.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03646227 (Multi-Drug Resistant Organism Network - MDRO Network), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-Drug Resistant Organism Network - MDRO Network
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThis study provides the first prospective, genomically validated dataset integrated into the global MultiDrug-Resistant Organism (MDRO) Network from the Middle East and North Africa region. To address the substantial gap in antimicrobial resistance (AMR) data, the American University of Beirut Medical Center (AUBMC) investigated carbapenem-resistant Enterobacterales (CRE), Acinetobacter baumannii (CRAB), and Pseudomonas aeruginosa (CRPA).
methodsConsecutive, hospitalized patients whose clinical cultures were positive for CRE, CRAB, or CRPA were prospectively enrolled between June 2018 and November 2019. Data on demographics, hospitalization, outcomes, and antimicrobial susceptibility were collected. Whole-genome sequencing (WGS) characterized the isolates. The primary outcome was the Desirability of Outcome Ranking (DOOR).
resultsNinety-four patients were included: 35 with CRE, 19 with CRAB, and 40 with CRPA. Overall, 30% of patients survived without adverse events, whereas 33% experienced two or more adverse events. Patients with CRAB had the poorest prognosis, with only 5% surviving without complications, and a significantly different DOOR distribution versus CRE or CRPA (p = 0.023). Adjusted DOOR probabilities confirmed the poorer outcomes associated with CRAB: when compared with CRE or CRPA, a randomly selected CRAB patient had only a 37.7% (95% CI, 24.9-52.6%) and 38.8% (95% CI, 26.5-52.7%) probability of achieving a more desirable outcome, respectively. WGS identified bla
conclusionsMDRO infections in Lebanon have distinct molecular patterns compared to the US, Chinese, South American, and Australian cohorts, as well as poor outcomes, especially with CRAB. Ongoing surveillance, strengthening regional collaboration, and future clinical trials are essential to guide diagnostic and therapeutic strategies in settings with increasing AMR. TRIAL REGISTRY: ClinicalTrials.gov. TRIAL REGISTRATION NUMBER: NCT03646227. DATE OF REGISTRATION: 15-08-2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.